Participate in a Clinical Trial

Greater Delaware Valley Chapter

Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing, and treating T1D. There are many opportunities in the Greater Delaware Valley area to participate in a T1D clinical trial close to home. See below for active opportunities.

Additionally, Breakthrough T1D has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting breakthrought1d.org/impact/research/clinical-trials today!

If you have any questions, please contact our Greater Delaware Valley Chapter Clinical Trials Education Volunteer, Ryan Chompre.

Ryan serves as a Clinical Trials Education Volunteer (CTEV) with Breakthrough T1D, driven by a personal connection to the mission – he has lived with T1D since the age of 13. With firsthand experience managing the condition, Ryan brings empathy and a deep commitment to helping others navigate their T1D journey. After discovering that (1) many people with T1D want to participate in clinical trials but are not aware of the opportunities to participate and (2) up to 80 percent of T1D clinical trials are slowed due to patient recruitment, Ryan was inspired to take on this volunteer position. In this role, he educates individuals and families about the importance of clinical research, helping them understand opportunities to participate in trials that are shaping the future of T1D treatment and care.

Ryan lives in Glen Mills, PA, and enjoys playing basketball, mountain biking, board games, and spending time with family. With a strong passion for science and medicine, Ryan aspires to become a Pediatric Endocrinologist!

 

 

GREATER DELAWARE VALLEY FEATURED STUDIES

 

DISEASE-MODIFYING THERAPIES:

The FABULINUS study (FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy) is recruiting participants ages 12-35 within 90 days of diagnosis with at least 1 T1D autoantibody. The study is evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.

 

CELL THERAPIES:

FORWARD Study – A Safety, Tolerability, and Efficacy Study of VX-880 (Zimislecel) in Participants with Type 1 Diabetes

The FORWARD study will evaluate the safety, tolerability, and efficacy of VX-880 (Zimislecel) infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

 

IMPROVING LIVES:

INHALE-AIDEx Study – Effect of Inhaled Technosphere vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults with T1D Using Automated Insulin Delivery

THE INHALE-AIDEx study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology (“Control-IQ” which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

 

CATT1 Study – Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

The CATT1 study is a 26-week, Phase 3 trial designed to measure the relative efficacy of adjunctive treatment with cadisegliatin to reduce the incidence of Level 2 or Level 3 hypoglycemia in participants with Type 1 Diabetes Mellitus compared to placebo (insulin alone) over 26 weeks of continuous therapy.

 

ONWARDS 11 Study – A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

The ONWARDS 11 study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

 

CLEAR Study – Closed Loop and Education for Hypoglycemia Awareness Restoration

The purpose of the CLEAR study is to determine the effect of counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D and rises with increasing duration of T1D.

 

ZONE Study – A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

The goal of the ZONE study is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars (“hypos”) at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured.

 

SURPASS-T1D-1 – A Study of Tirzepatide Compared with Placebo in Adults with Type 1 Diabetes and Obesity or Overweight

The main purpose of the SURPASS-T1D-1 study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

 

SCREENING:

Trial Net screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.

 

ASK (Autoimmunity Screening for Kids) is offering health screening to detect Type 1 Diabetes (T1D) and Celiac Disease (CD) at no cost to you. ASK is available to all U.S. children (ages 1–17) and adults with or without a family history of these conditions. ​

 

VIRTUAL:

Researchers at Vanderbilt University are conducting a study on digital storytelling for teens with T1D. They are recruiting participants aged 13-21 living with T1D for at least 1 year. The study will explore how creating personal stories about living with T1D can help with managing stress, feeling supported, and improving self-care.

Researchers at Yale School of Public Health are recruiting English-speaking participants aged 18+ living with T1D for at least 1 year to complete a survey on Type 1 Diabetes Stigma.

The University of Minnesota is recruiting participants aged 18-65 living with T1D for at least 1 year with an A1C between 7.5-14% for the FAM study (Follower, Action Plan, and Remote Monitoring). T1Ds and their “Follower” (family member, friend, or caregiver) will participate together in 4+ sessions with a Certified Diabetes Care and Education Specialist over 90 days to see if behavioral and digital health intervention helps reduce diabetes distress and improve glycemia.

The T1DAL study is recruiting participants aged 13-18 living with T1D for at least 6 months. The goal of the TIDAL Study is to test out a new healthy lifestyles program designed specifically for teenagers with type 1 diabetes. The program is a virtual, group-based program for 16 weeks.

The ReDUCe study (Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes) is recruiting participants 18-64 living with T1D for at least 6 months with an A1C > 7.5%. The study will use telemedicine-delivered cognitive-behavioral therapy (CBT) enhanced with continuous glucose monitor (CGM) review to target diabetes distress in adults with type 1 diabetes.

Stanford University’s Time in Tight Range Study is recruiting participants 18 and older to complete an anonymous survey about their views on a new metric to assess diabetes outcomes.

Transdisciplinary Care for Transition (TCT) is recruiting participants ages 17-25 living with T1D for at least 6 months who are approaching discharge from pediatric diabetes healthcare. The TCT is a research study that examines the impact of meeting with a diabetes educator, psychologist, and social worker during the transition from pediatric to adult diabetes care.

 The Boston College Connell School of Nursing is recruiting English speaking T1Ds ages 18-30 to share their experiences coping with the costs of managing diabetes.

The CGM Data Sharing Older Adults study is recruiting participants aged 60+ currently using a CGM with an A1C of 7.5-11%. The purpose of this study is to test the Share plus intervention aimed at improving the use of data sharing between people with diabetes and their care partners in order to maximize the benefits of continuous glucose monitoring.

The Diabetes Care in School survey is recruiting caregivers of school-aged T1Ds. This survey was developed to assess the experience of families with children and adolescents with type 1 diabetes and their care during the school period. It was translated into different languages and will be shared in various parts of the world, identifying the barriers to diabetes care during the school period in different countries and guiding the measures that can be taken to improve school diabetes care globally. 

The TIDES study is recruiting participants aged 13-17 living with T1D. Researchers at the Miriam Hospital are interested in learning how teens answer questions related to eating and diabetes management. The goal of this study is to create a questionnaire about eating and diabetes specifically for persons with type 1 diabetes that can be used in clinics and other research studies.

The Diabetes Teen Wellness study is recruiting female-identifying T1Ds aged 11-17 using a CGM. The Diabetes Wellness Teen Study is investigating risk factors that predict the future onset of body image and eating behavior concerns in adolescents with type 1 diabetes.

The UP-CBT (Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression is recruiting participants aged 18-35 living with T1D for > 6 months, A1C 7.5-14%, with anxiety or depressive mood disorder. This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in young adults with type 1 diabetes.

The Diabetes Body Acceptance Project is conducting a research study comparing two programs designed to improve body acceptance, reduce body image concerns, and reduce disordered eating behaviors. Female-identifying individuals between the ages of 15-30 with T1D who have body image concerns and/or struggle with disordered eating behaviors are invited to participate. Depending on the program you are randomized to you will attend weekly one-hour groups for 6 weeks (virtual or in-person) or watch one hour of videos each week.

University of California, San Francisco is running a virtual study Extended Bolus for Meals in a Closed-Loop System for participants ages 13-18 who use Control IQ to look at the impact of bolus timing on fat/protein.

The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants can sign up for other studies on various topics related to type 1 diabetes.

Clinical Trials Connection